Literature DB >> 6585273

Phase II trial of 4-demethoxydaunorubicin in advanced colorectal carcinoma.

H D Harper, N E Kemeny, T Ahmed, E Cheng, F Arena, P Sordillo, L Faye.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1984        PMID： 6585273

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN： 0361-5960


× No keyword cloud information.
  4 in total

Review 1.  Idarubicin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the chemotherapy of cancer.

Authors:  L M Hollingshead; D Faulds
Journal:  Drugs       Date:  1991-10       Impact factor: 9.546

Review 2.  Anthracycline analogs: the past, present, and future.

Authors:  R B Weiss; G Sarosy; K Clagett-Carr; M Russo; B Leyland-Jones
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

Review 3.  Oral idarubicin--an anthracycline derivative with unique properties.

Authors:  M Goebel
Journal:  Ann Hematol       Date:  1993-01       Impact factor: 3.673

Review 4.  Idarubicin (4-demethoxydaunorubicin). A preliminary overview of preclinical and clinical studies.

Authors:  F Ganzina; M A Pacciarini; N Di Pietro
Journal:  Invest New Drugs       Date:  1986       Impact factor: 3.850
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.